Anti-BAFFR antibody reduced atherosclerosis in hyperlipidemic ApoE^−/− mice with established atherosclerosis.

<p>Despite (A) body weight and (B) comparable plasma lipids, anti-BAFFR antibody ameliorate atherosclerosis in ApoE^−/− mice with established atherosclerosis assessed by (F) Oil Red-O stained lipid accumulation and total lesion area and (G) CD68⁺ macrophage accumulation. (C-D) peritoneal B1a B cells unaffected, representative FACS image show that CD22⁺ CD5⁺ peritoneal b1a cells were unaffected. (E) CD4⁺, CD8⁺, NK1.1⁺ (NK) and NK1.1⁺ TCRβ⁺ (NKT) cells and CD4⁺ CD25⁺ foxp3⁺ regulatory T cells (T-reg) in spleens unaffected n = 7–9 mice per each group * p&lt;0.05 □ control IgG treated mice; ▪ BAFFR-antibody treated mice.